Aster DM Healthcare Q3 FY26 Earnings Call Transcript Released
Aster DM Healthcare released its Q3 FY26 earnings call transcript. The combined proforma entity reported a 15% revenue growth to ₹2,366 crore and a 22% EBITDA increase to ₹503 crore. Aster's standalone revenue grew 13% to ₹1,186 crore. The merger with Quality Care India is progressing, with completion expected in Q1 FY27. Capacity expansion plans include adding over 4,000 beds.
The transcript provides detailed financial performance and strategic updates, including merger progress and expansion plans, which are material for investors and analysts. This information can influence investment decisions.
The announcement is a transcript release of an earnings call, which is a routine disclosure. While the financial performance discussed was positive, the release itself is factual and neutral in tone.
Aster DM Healthcare Limited has released the transcript of its earnings conference call for the quarter and nine months ended December 31, 2025. The call, held on February 2, 2026, featured management including Ms. Alisha Moopen (Deputy Managing Director) and Mr. Varun Khanna (Group MD & CEO, QCIL), among others.
During the call, the management discussed the combined proforma performance of Aster and Quality Care India Limited (QCIL), highlighting a 15% year-on-year revenue growth to ₹2,366 crore and a 22% increase in operating EBITDA to ₹503 crore for Q3 FY26. This performance was attributed to growth in patient volumes, improved case mix, and cost management.
The company also provided an update on the proposed merger with Quality Care India Limited, noting that the merger application was filed with the NCLT on December 11, 2025. The shareholders' meeting to approve the scheme is expected between February 27, 2026, and March 13, 2026, with the merger anticipated to be completed in Q1 FY27.
Aster's standalone performance for Q3 FY26 showed a 13% year-on-year revenue increase to ₹1,186 crore, with operating EBITDA at ₹224 crore. The commissioning of the Kasargod hospital was noted as a contributor to revenue growth. Oncology revenues grew by 27% and Medical Value Travel segment by 41% year-on-year.
QCIL reported a strong Q3 FY26 performance with revenue rising 17.3% year-on-year to ₹1,181 crore and post-Ind AS EBITDA increasing by 32.0% to ₹279 crore, with EBITDA margins expanding to 23.7%.
The management also discussed capacity expansion plans, with Aster planning to add over 2,300 beds and QCIL planning to add over 1,700 beds in the coming years. Investments in advanced technologies like linear accelerators and robotic surgery systems were also highlighted.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.